908 Devices 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- 908 Devices reported 3rd quarter 2026 revenue of $19 million, up 35% year over year from $14 million, driven primarily by FTIR products and Nearlab law enforcement revenue.
- The company shipped more than 300 devices in the quarter, a record, and ended Q3 with an installed base of approximately 4,400 devices; it reported $5.1 million in recurring revenue, 27% of total revenue.
- Gross profit was $10 million and gross margin was 53%; adjusted gross profit was $10.9 million and adjusted gross margin was 58%, down 40 basis points year over year, primarily due to mix led by lower margin international product revenues.
- Adjusted EBITDA loss was $1.7 million, compared with a loss of $1.8 million in the prior-year period; net loss from continuing operations was $4.6 million, compared with $14.9 million.
- The company consumed $2.4 million in cash during Q3 and ended the quarter with $99.1 million in cash, cash equivalents, and marketable securities, with no debt outstanding.
- FTIR products represented 55% of Q3 revenue. For the first 9 months of 2026, FTIR was 49%, mass spec was 47%, and Nearlab was 4% of total revenue.
- International customers represented 40% of Q3 revenue, double the prior year; U.S. state and local customers represented approximately 25% of Q3 revenue and over 40% year to date.
- 908 Devices sold approximately 100 Nearlab devices in Q3, more than half to customers new to Nearlab, and surpassed 1 million cumulative scans on the Nearlab narcotics platform; daily scan volume averaged roughly 1 per minute, up 74% year over year.
- The company shipped more than 200 FTR devices in Q3, including approximately 2/3 of the $6 million Protector order from an Asia-Pacific corrections agency. It also secured a European defense framework agreement worth more than $2 million and another European government competitive displacement win.
- A U.S. military customer purchased dozens of MX908 devices for aerosol detection, and 908 Devices delivered MX908 devices to the Office of the US Army's Capability Program Executive Sir CBRN Defense for analytical testing and evaluation.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Hello, everyone. Thank you for joining us, and welcome to the 908 Devices Third Quarter 2026 Financial Results Conference Call. After today's prepared remarks, we will host a question-and-answer session. If you would like to ask a question, please press star one to raise your hand. To withdraw your question, press star one again. I will now hand the conference over to Matt Roache, Vice President Investor Relations. Matt, please go ahead. Thank you and good morning.
On this call, we will be discussing our financial results for the third quarter of 2026, which were released earlier this morning. Joining me from 908 Devices are Kevin Knopp, Chief Executive Officer and Co-Founder, and Joe Griffith, Chief Financial Officer. During today's call, we will make forward-looking statements within the meaning of federal securities laws. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated. For discussion of these risks and uncertainties, please review the forward-looking statement disclosure in the earnings news release, as well as in our most recent annual report on Form 10-K, quarterly report on Form 10-Q, and other SEC filings. These forward-looking statements reflect management's beliefs and assumptions as of the date of this live broadcast, November 10, 2026.
Except as required by law, we disclaim any obligation to update forward-looking statements to reflect future events or circumstances. Our commentary today will also include non-GAAP financial measures, which should be considered as a supplement to and not a substitute for GAAP financial measures. The non-GAAP reconciliations can be found in today's earnings press release, which is available in the investor relations section of our website. With that, I'll now turn the call over to Kevin.
Thanks, Matt. Good morning, and thank you for joining our third quarter 2026 earnings call. Q3 was a strong quarter across the board. We delivered revenue of $19 million, up 35% year-over-year, driven by continued strength in our core business and underscoring the durability and momentum of the platform we've been building. Reflecting that momentum, we're raising the low end of our full year 2026 revenue guidance and now expect revenue of $68.5 million-$70 million. We shipped more than 300 devices in the quarter, a new company record, bringing our installed base to approximately 4,400 devices in the field. This milestone reflects broadening adoption across frontline responders, fire and hazmat teams, law enforcement, and federal and military customers in the U.S. and abroad, as customers accelerate efforts to modernize their detection capabilities and stay ahead of an evolving threat landscape.
On profitability, the structural changes we made in 2025 fundamentally reset our cost base. We are now operating with the control and discipline to invest behind our growth opportunity without overspending, prioritizing growth while making steady progress towards adjusted EBITDA breakeven. Our Q3 adjusted EBITDA loss was $1.7 million, and we remain on track to reduce our full year loss to the mid-single digit millions, cutting it roughly by one-third from 2025, inclusive of NIRLab. Turning to NIRLab, the integration is on track and executing well. Commercial synergies are already translating into accelerated adoption, and the pipeline continues to build. We are seeing strong interest in the U.S. and are making good progress with international law enforcement agencies, giving us confidence in the trajectory ahead. Stepping back, I am proud of how our team executed in Q3.
We expanded our market footprint and continued to demonstrate operating discipline as we build a category-defining company. In the quarter, we made solid progress on our three focus areas for 2026: scaling our proven platforms, extending platform leadership, and strengthening revenue durability through connected services. We are well-positioned to deliver a strong finish to the year. Let me now walk through our progress in each of those areas. First, scale our proven platforms. Our product platforms are the engine of our growth, and Q3 demonstrated what they can deliver. We shipped more than 200 FTIR devices in the quarter, including approximately two-thirds of the $6 million ProtectIR order from an Asia-Pacific correction agency we highlighted on our Q2 earnings call. In Europe, we secured two meaningful ProtectIR wins with government customers, both with explosive ordnance disposal, or EOD, teams.
The first is a framework agreement worth more than $2 million with a defense customer replacing legacy equipment. The second is a competitive displacement win with another European government. Together, these wins demonstrate that ProtectIR is earning trust in demanding environments and capturing share in the global EOD modernization cycle. International customers represented 40% of total revenues in the third quarter, double the prior year, reflecting the strength of our technology, our investments in international channels, and expanding global defense budgets. VipIR is also scaling. We remain on track to ship more than 100 VipIR units this year. In Q3, a major U.S. transportation agency placed its first VipIR order, notable because it already deploys our MX908, XplorIR, and ThreatID devices. This is a land and expand in action. Each of our platforms serves a distinct detection or identification mission, and our products don't compete with one another.
They work together. When a customer adds another 908 platform, they are expanding their detection coverage and addressing more of their workflow, not replacing what they already have. This agency is a clear example of that dynamic, multi-system orders and adoption, and it's a pattern we are increasingly seeing across our customer base. Our flagship MX908 is another proven platform that continues to scale with our customers' needs, and the illicit drug landscape is making that more apparent than ever. On our last call, we mentioned a new class of synthetic opioids called orphines. The latest example is cyclorphine, estimated to be up to 10 times more potent than fentanyl. A recent Newsweek article highlighted that it's been linked to deaths across the U.S. and detected in 17 countries. It's frequently found in counterfeit pills and often requires multiple doses of NARCAN to reverse an overdose.
What makes cyclorphine and the many new synthetic compounds like it particularly dangerous is that they can outpace fixed field detection methods. Responders need programmable technology that evolves with the threat, and that's what MX908 uniquely delivers. Because it uses mass spectrometry to identify substances by molecular signature, we can update its library as new threats emerge, giving frontline responders the ability to identify these drugs in the field at trace levels in real time. This is a compelling example of how our installed base becomes more valuable over time. The same device helping responders address fentanyl today is already helping them get ahead of the next wave of threats. As we extend connected services across our portfolio, cloud subscriptions will make keeping customers current faster and more seamless, a model NIRLab already delivers today, as I'll discuss later in my remarks.
Turning to our second focus area, extend platform leadership. A clear example of our differentiated capabilities is in aerosol detection. The chemical threat landscape is shifting. A-Series nerve agents and pharmaceutical-based agents are a growing concern, and they can be deployed as aerosols, a form that conventional vapor detectors aren't designed to catch. As a handheld mass spectrometer, MX908 is uniquely able to detect and identify these threats at trace levels in both aerosol and vapor form, and that capability is resonating with customers. In Q3, a U.S. military customer purchased dozens of MX908 devices to close an immediate capability gap, working to get the technology quickly into the hands of war fighters, and we're already discussing follow-on orders. In parallel and building on the next steps we outlined last quarter, we made tangible progress on AVCAD.
We delivered MX908 devices to the office of the U.S. Army's Capability Program Executive for CBRN Defense for analytical testing and evaluation. This is the organization responsible for the AVCAD program, and as we discussed last quarter, the government is considering commercially available products as part of a broader Department of Defense procurement reform, prioritizing speed and program flexibility. We view this testing as a constructive signal for the program's trajectory and believe it positions us well for potential commercial off-the-shelf or COTS orders in 2027. We believe our aerosol and vapor detection technology is best in class, extensively government tested and validated, and can win this opportunity regardless of the chosen path. We continue to see meeting the military's next-generation aerosol and vapor detection needs as a significant long-term opportunity. And with the commercial path, more of the program economics would come to 908 Devices.
Meeting next-generation needs is what drives our roadmap, starting with our next-generation MX908, which we're targeting to begin shipping to early access customers by year-end. It is significantly smaller and lighter, more selective, simpler to operate, and features enhanced connected services, building on the capabilities that make MX908 the trusted choice in the field today. Pilot manufacturing is underway. Beta feedback from users in the U.S. and internationally has been overwhelmingly positive, and our partners across Europe, the Middle East, and Latin America are already asking for demo units. We expect the next-generation MX908 to be a meaningful growth driver in 2027, winning new customers and, over time, driving upgrades across our installed base of more than 3,000 MX908 devices. Finally, our third strategic focus area is strengthening revenue durability, building a more predictable revenue mix through recurring revenue from connected services alongside our OEM and funded partnerships.
Today, I will focus on NIRLab, which is central to our connected services vision, and Q3 showed real momentum. We sold approximately 100 NIRLab devices in the quarter, up from approximately 35 devices in the first two months of ownership. More than half went to customers new to NIRLab, including U.S. state and local agencies, some of them new to 908 Devices entirely, as well as law enforcement agencies across Europe, Australia, Africa, and Asia. Demand is broad-based, not concentrated into any single market. Platform usage is growing even faster, and that is a key metric for us. The more agencies rely on NIRLab every day, the more durable and valuable the subscription becomes. In Q3, we surpassed 1 million cumulative scans on the NIRLab narcotics platform. Daily scan volume now averages roughly one per minute, up 74% year-over-year.
We have also begun collaborating with U.S. forensics labs, giving NIRLab's AI-powered models more U.S. data to train on, so identification keeps getting more refined and stays current as we grow in the U.S. That matters because the drug landscape changes quickly, and NIRLab's cloud-connected architecture is purpose-built for exactly that reality. The deaths of two Mississippi college students in September, linked by authorities to synthetic kratom, are another tragic reminder of how rapidly new threats emerge. Policy is responding. Earlier this year, a bipartisan group of U.S. senators urged the DEA and FDA to accelerate controls on synthetic kratom compounds, and the DEA has since proposed new federal limits. As regulation tightens, agencies will need fast, reliable field identification. NIRLab has unique capabilities to detect kratom today, and its cloud-connected library allows us to push updates to customers as new threats emerge without requiring new hardware.
Longer term, we envision a connected experience where customers can share results and trends, manage their fleet, and analyze data across every 908 Device, one workflow, whichever device is in hand. Team Leader connects our FTIR products today and will extend to our next-generation MX908, with NIRLab's cloud infrastructure and advancements helping us bring that experience across the entire portfolio. This is the blueprint for where we are taking the broader business: rugged hardware paired with connected software that generates recurring revenue, backed by the 24/7 expert ReachBack support from our scientists that our customers consistently rank as most valuable. That integrated model of hardware, software, and expertise is the template we intend to apply across the portfolio. With that, I will turn it over to Joe to walk through the detailed financial results for the quarter.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
10 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
